JP2005525352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525352A5 JP2005525352A5 JP2003570776A JP2003570776A JP2005525352A5 JP 2005525352 A5 JP2005525352 A5 JP 2005525352A5 JP 2003570776 A JP2003570776 A JP 2003570776A JP 2003570776 A JP2003570776 A JP 2003570776A JP 2005525352 A5 JP2005525352 A5 JP 2005525352A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- vegfr
- composition according
- inhibitor
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/081,126 US20030180294A1 (en) | 2002-02-22 | 2002-02-22 | Methods of extending corneal graft survival |
| PCT/US2003/005125 WO2003072029A2 (en) | 2002-02-22 | 2003-02-20 | Methods of extending corneal graft survival |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005525352A JP2005525352A (ja) | 2005-08-25 |
| JP2005525352A5 true JP2005525352A5 (https=) | 2006-04-06 |
Family
ID=27765253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003570776A Pending JP2005525352A (ja) | 2002-02-22 | 2003-02-20 | 角膜移植片の生存を延長させる方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20030180294A1 (https=) |
| EP (1) | EP1476187A4 (https=) |
| JP (1) | JP2005525352A (https=) |
| AU (1) | AU2003215337B2 (https=) |
| CA (1) | CA2476994A1 (https=) |
| WO (1) | WO2003072029A2 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6824777B1 (en) | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| EP1353952B1 (en) | 1994-11-14 | 2007-04-11 | Ludwig Institute For Cancer Research | Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy |
| US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
| KR100402497B1 (ko) * | 2000-11-30 | 2003-10-22 | 주식회사 엘지이아이 | 전자레인지의 가열장치 |
| US7611711B2 (en) * | 2001-01-17 | 2009-11-03 | Vegenics Limited | VEGFR-3 inhibitor materials and methods |
| US6709655B2 (en) | 2001-02-28 | 2004-03-23 | Instituto Bioclon, S.A. De C.V. | Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof |
| WO2003006104A2 (en) * | 2001-07-12 | 2003-01-23 | Ludwig Institute For Cancer Research | Lymphatic endothelial cells materials and methods |
| US20040214766A1 (en) * | 2001-10-01 | 2004-10-28 | Kari Alitalo | VEGF-C or VEGF-D materials and methods for treatment of neuropathologies |
| US20030113324A1 (en) * | 2001-10-01 | 2003-06-19 | Kari Alitalo | Neuropilin/VEGF-C/VEGFR-3 materials and methods |
| US20040248796A1 (en) * | 2003-02-04 | 2004-12-09 | Kari Alitalo | VEGF-B and PDGF modulation of stem cells |
| AU2004242586C1 (en) * | 2003-05-28 | 2011-02-24 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using VEGF antagonists |
| EP1635860A2 (en) * | 2003-06-12 | 2006-03-22 | Ludwig Institute For Cancer Research | Use of vegf-c or vegf-d in reconstructive surgery |
| WO2005016963A2 (en) * | 2003-06-12 | 2005-02-24 | Ludwig Institute For Cancer Research | Heparin binding veger-3 ligands |
| US20060210563A1 (en) * | 2003-07-25 | 2006-09-21 | Juan Lopez De Silanes | Administration of anti-cytokine f(ab')2 antibody fragments |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US7303748B2 (en) | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| US20080070855A1 (en) * | 2006-09-20 | 2008-03-20 | James Pitzer Gills | Treatment with anti-VEGF agents to prevent postoperative inflammation and angiogenesis in normal and diseased eyes |
| US9073997B2 (en) * | 2007-02-02 | 2015-07-07 | Vegenics Pty Limited | Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis |
| CN101815504B (zh) | 2007-07-10 | 2013-11-20 | 加利福尼亚大学董事会 | 用于向所选择组织递送组合物的材料和方法 |
| WO2009061830A1 (en) * | 2007-11-06 | 2009-05-14 | Massachusetts Eye & Ear Infirmary | Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor |
| EP2538965B1 (en) * | 2010-02-25 | 2017-04-12 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
| JP6105838B2 (ja) * | 2010-08-24 | 2017-03-29 | 国立大学法人 岡山大学 | 疼痛の治療剤 |
| US9364535B2 (en) * | 2012-08-15 | 2016-06-14 | The Regents Of The University Of California | Methods and compositions for modulating lymphangiogenesis, e.g., to treat transplant rejection, in a subject |
| PT2956476T (pt) | 2013-02-18 | 2020-02-21 | Vegenics Pty Ltd | Moléculas de ligação e usos destas |
| JP2020503255A (ja) * | 2016-10-27 | 2020-01-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インテグリンアルファ９の遮断はリンパ弁形成を抑制し、移植片の生存を促進する |
| CN119055769B (zh) * | 2023-08-17 | 2025-09-05 | 南方医科大学南方医院 | 抗血管生成药物在提高软组织移植物保留率中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| AU2002236495B2 (en) * | 2000-11-29 | 2006-05-11 | Allergan, Inc. | Intraocular implants for preventing transplant rejection in the eye |
| DE10134196B4 (de) * | 2001-07-13 | 2005-08-18 | Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt | Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen |
-
2002
- 2002-02-22 US US10/081,126 patent/US20030180294A1/en not_active Abandoned
-
2003
- 2003-02-20 EP EP03711158A patent/EP1476187A4/en not_active Withdrawn
- 2003-02-20 WO PCT/US2003/005125 patent/WO2003072029A2/en not_active Ceased
- 2003-02-20 JP JP2003570776A patent/JP2005525352A/ja active Pending
- 2003-02-20 AU AU2003215337A patent/AU2003215337B2/en not_active Ceased
- 2003-02-20 CA CA002476994A patent/CA2476994A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005525352A5 (https=) | ||
| Seferian et al. | Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? | |
| Bonegio et al. | Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy | |
| Huang et al. | Upregulation of angiotensin‐converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors | |
| US20190022225A1 (en) | Protocol for increasing life expectancy in a test subject | |
| KR20040093058A (ko) | Ｎ-(5-(4-(4-메틸-피페라지노-메틸)-벤조일아미도-2-메틸페닐)-4-(3-피리딜)-2-피리미딘-아민 코팅된 스텐트 | |
| BR0207321A (pt) | Implantes com fk506 | |
| ATE504288T1 (de) | Oros-push-stick für die kontrollierte abgabe von wirkstoffen | |
| NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
| AU2011322597B2 (en) | Dosing regimes for the treatment of ocular vascular disease | |
| MY147310A (en) | A solid pharmaceutical composition containing 2-ethoxy-1-{ [2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl]methyl}-1h-benzimidazole-7-carboxylic acid or a salt thereof, a fat and oil-like substace having low melting point and a low viscosity binder | |
| BRPI0714815A2 (pt) | composiÇço, e, uso de um (a) agonista e (b) um agente anti-infeccioso | |
| JP2007502327A5 (https=) | ||
| KR20160079918A (ko) | Ｖｅｇｆ 억제제 및 이리노테칸을 함유하는 항종양 조합물 | |
| CN111343980A (zh) | 右美沙芬经皮递送装置 | |
| US20160151406A1 (en) | Combination cancer therapy with c-met inhibitors and synthetic oligonucleotides | |
| Grice et al. | Drug delivery options and therapeutic advances in the management of erectile dysfunction | |
| EP2029139B1 (en) | Use of a p38 kinase inhibitor for treating psychiatric disorders | |
| EP1152002A4 (en) | PYRROL DERIVATIVES AND CELL DEATH INHIBITORS | |
| EP3804724B1 (en) | Cdk inhibitors for treating pah | |
| JP2008521866A (ja) | Ｖｅｇｆ阻害剤および５ｆｕまたはこの誘導体の１つを含有する抗腫瘍組合せ物 | |
| Casserly et al. | C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade | |
| ATE446309T1 (de) | Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung | |
| JP2010539173A (ja) | サイクリン依存キナーゼ阻害化合物を含む製剤およびこの製剤を用いて腫瘍を処置する方法 | |
| CN100506230C (zh) | 血管内膜增厚抑制剂 |